RxDoctor Payments Data

Ernesto Napoles, APRN

Nurse Practitioner · Atlanta, GANPI 1528554003

Payments from drug & device makers

$955in general payments, 2019–2025

Across 28 payments — averaging $34.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biosense Webster, Inc.$186
  • Sanofi$128
  • E.r. Squibb & Sons, L.L.C.$125
  • AstraZeneca$124
  • Gilead$63
  • Beigene USA, Inc.$58
  • plus $271 from 9 others

What the payments were for

  • Food & beverage$955100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$955 in reported general payments places this provider in the 75th percentile of 3,328 nurse practitioner providers in Georgia.

See all nurse practitioner providers in Georgia

Medicare billing

Part B allowed, 2024
$3,780
Medicare patients
28
Services billed
43

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CalquenceAcalabrutinib Maleate20$270,302
BrukinsaZanubrutinib23$255,989
VenclextaVenetoclax20$52,350
EliquisApixaban61$37,543
Posaconazole15$10,487
Acyclovir153$2,114
ValacyclovirValacyclovir Hcl21$849
Ondansetron Hcl20$428
Pantoprazole Sodium65$305
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim51$236
Triamcinolone Acetonide20$205
Gabapentin13$168
Prednisone53$138
Allopurinol15$133
Methylprednisolone20$99

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaCalquence$124$270,30220 claims
Beigene USA, Inc.Brukinsa$58$255,98923 claims
AbbVieVenclexta$19$52,35020 claims
PfizerEliquis$53$37,54361 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 3,328 nurse practitioner providers in Georgia.

Other nurse practitioner in Atlanta

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →